Comparison of Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch in Immunocompromised Children and Healthy Adults
Timothy A. Driscoll(Duke Medical Center), Ping Liu(Nanjing University of Chinese Medicine), Antonio Arrieta(Children's Hospital of Orange County), Alice Baruch(Pfizer (United States)), Scott M. Bradfield, Lolie C. Yu(Louisiana State University), Robert A. Krance(Baylor College of Medicine), Jeffrey L. Blumer(University of Toledo), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Michael L. Graham(University of Arizona), Eneida R. Nemecek(Oregon Health & Science University)
Cited by 63
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369